Merck & Company Inc (MRK)vsProtalix Biotherapeutics Inc (PLX)
MRK
Merck & Company Inc
$113.56
+0.36%
HEALTHCARE · Cap: $277.02B
PLX
Protalix Biotherapeutics Inc
$2.02
+3.06%
HEALTHCARE · Cap: $170.81M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 124593% more annual revenue ($65.77B vs $52.74M). MRK leads profitability with a 13.6% profit margin vs -12.5%. MRK earns a higher WallStSmart Score of 53/100 (C-).
MRK
Buy53
out of 100
Grade: C-
PLX
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-15.7%
Fair Value
$97.76
Current Price
$113.56
$15.80 premium
Margin of Safety
-3.9%
Fair Value
$2.81
Current Price
$2.02
$0.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 38.1%
Generating 2.9B in free cash flow
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Weak financial health signals
Expensive relative to growth rate
Smaller company, higher risk/reward
ROE of -14.4% — below average capital efficiency
Revenue declined 49.9%
Earnings declined 1.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin.
Bull Case : PLX
PLX has a balanced fundamental profile.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Bear Case : PLX
The primary concerns for PLX are Market Cap, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
MRK profiles as a value stock while PLX is a turnaround play — different risk/reward profiles.
MRK carries more volatility with a beta of 0.28 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (53/100 vs 18/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Protalix Biotherapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?